

Resource Summary Report

Generated by [NIF](#) on Sep 1, 2026

NOD.Cg-Rag1^{tm1Mom} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/J

RRID:IMSR_JAX:024099

Type: Organism

Proper Citation

RRID:IMSR_JAX:024099

Organism Information

URL: <https://www.jax.org/strain/024099>

Proper Citation: RRID:IMSR_JAX:024099

Description: Mus musculus with name NOD.Cg-Rag1^{tm1Mom} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/J from IMSR.

Species: Mus musculus

Synonyms: NRGs. NRG-3GS. NRG-SGM3

Notes: gene symbol note: interleukin 2 receptor; gamma chain|recombination activating 1|interleukin 3|cytomegalovirus|KIT ligand|transgene insertion 1; CJ Eaves|colony stimulating factor 2; mutant strain|congenic strain: Il2rg|Rag1|IL3|CMV|KITLG|Tg(CMV-IL3;CSF2;KITLG)1Eav|CSF2

Affected Gene: interleukin 2 receptor; gamma chain|recombination activating 1|interleukin 3|cytomegalovirus|KIT ligand|transgene insertion 1; CJ Eaves|colony stimulating factor 2

Genomic Alteration: targeted mutation 1; Warren J Leonard|targeted mutation 1; Peter Mombaerts|transgene insertion 1; CJ Eaves

Catalog Number: JAX:024099

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Rag1^{tm1Mom} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/J

Record Creation Time: 20250513T053749+0000

Record Last Update: 20260829T045053+0000

Ratings and Alerts

No rating or validation information has been found for NOD.Cg-Rag1^{tm1Mom} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/J.

No alerts have been found for NOD.Cg-Rag1^{tm1Mom} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Kincross H, et al. (2026) Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1. The Journal of clinical investigation, 136(2).

Le BV, et al. (2026) Pol γ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia. Cell reports. Medicine, 7(3), 102687.

Li W, et al. (2025) FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia. Science advances, 11(33), eadv7648.

Donnelly H, et al. (2024) Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells. Nature communications, 15(1), 5791.

Chen M, et al. (2024) Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. Cell reports. Medicine, 5(7), 101645.

Chan AKN, et al. (2024) Therapeutic targeting Tudor domains in leukemia via CRISPR-Scan Assisted Drug Discovery. Science advances, 10(8), eadk3127.

Wiesheu R, et al. (2024) IL-27 maintains cytotoxic Ly6C⁺ $\gamma\delta$ T cells that arise from immature precursors. The EMBO journal, 43(14), 2878.

Dou X, et al. (2023) RBFOX2 recognizes N6-methyladenosine to suppress transcription and block myeloid leukaemia differentiation. Nature cell biology, 25(9), 1359.

Han L, et al. (2023) METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. *Cell stem cell*, 30(1), 52.

Li Y, et al. (2023) TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. *Cell stem cell*, 30(8), 1072.

Golla U, et al. (2021) DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. *Cancers*, 13(19).

Qing Y, et al. (2021) R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. *Molecular cell*, 81(5), 922.

Li Y, et al. (2020) Co-culture Systems of Drug-Treated Acute Myeloid Leukemia Cells and T Cells for In Vitro and In Vivo Study. *STAR protocols*, 1(2).

Su R, et al. (2020) Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. *Cancer cell*, 38(1), 79.